Document Detail

Advancing personalized cancer medicine in lung cancer.
MedLine Citation:
PMID:  23020726     Owner:  NLM     Status:  In-Data-Review    
Although improvements in genomic technologies during the past decade have greatly advanced our understanding of the genomic alterations that contribute to lung cancer, and the disease has (to a degree) become a paradigm for individualized cancer treatment in solid tumors, additional challenges must be addressed before the goal of personalized cancer therapy can become a reality for lung cancer patients.
Laura E Macconaill
Related Documents :
24768356 - Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine i...
20208286 - Perspectives on cancer screening among latino community members and internal medicine r...
24236006 - Quantitative network measures as biomarkers for classifying prostate cancer disease sta...
25031616 - The translation of cancer genomics: time for a revolution in clinical cancer care.
17192846 - R115777 (zarnestra)/zoledronic acid (zometa) cooperation on inhibition of prostate canc...
21828236 - Circulating markers of interstitial lung disease and subsequent risk of lung cancer.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Archives of pathology & laboratory medicine     Volume:  136     ISSN:  1543-2165     ISO Abbreviation:  Arch. Pathol. Lab. Med.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-01     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7607091     Medline TA:  Arch Pathol Lab Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1210-6     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Strategies for overcoming acquired resistance to epidermal growth factor receptor-targeted therapies...
Next Document:  The separation of benign and malignant mesothelial proliferations.